Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s.

Katherine Brimblecombe¹,²,³, Stephanie J Cragg¹,²,³

¹Department of Physiology, Anatomy and Genetics, University of Oxford, OX1 3PT, UK;
²Oxford Parkinson’s Disease Centre, University of Oxford, Oxford, United Kingdom;
³Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815

Cláudia C. Mendes

ABSTRACT

This collection contains three protocols detailing methods used in Brimblecombe, K.R. et al. (2023) *Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s*.

DOI:
dx.doi.org/10.17504/protocols.io.4r3l27dxg1y/v1

Collection Citation: Katherine Brimblecombe, Stephanie J Cragg 2023. Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s. protocols.io https://dx.doi.org/10.17504/protocols.io.4r3l27dxg1y/v1

License: This is an open access collection distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working
We use this collection and it's working